1. Home
  2. BQ vs OGEN Comparison

BQ vs OGEN Comparison

Compare BQ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

N/A

Current Price

$0.79

Market Cap

3.2M

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.61

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
OGEN
Founded
2008
1996
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
2.7M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
BQ
OGEN
Price
$0.79
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
169.7K
44.1K
Earning Date
01-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.50
52 Week High
$72.74
$9.16

Technical Indicators

Market Signals
Indicator
BQ
OGEN
Relative Strength Index (RSI) 51.17 49.44
Support Level $0.68 $0.56
Resistance Level $0.88 $0.66
Average True Range (ATR) 0.09 0.04
MACD 0.01 0.01
Stochastic Oscillator 57.19 56.53

Price Performance

Historical Comparison
BQ
OGEN

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: